Back to all news
UK Researchers Launch Unbiased AI Testing Platform for Diabetic Retinopathy Screening
Researchers unveiled a new independent platform for fair, large-scale evaluation of commercial AI algorithms detecting diabetic eye disease within the NHS.
Key Details
- 1First real-world head-to-head platform to evaluate commercial AI algorithms for NHS use in detecting diabetic eye disease.
- 2Eight CE marked AI algorithms tested on 1.2 million retinal images from one of the UK’s largest and most diverse screening programs.
- 3Algorithm performance (accuracy) ranged from 83.7% to 98.7% for clinically relevant diabetic eye disease, outperforming or matching human graders.
- 4Algorithms’ accuracy remained consistent across varied ethnic groups; first such assessment at this scale.
- 5AI analyzed images in 240ms–45s compared to up to 20 minutes for humans, vastly improving efficiency.
- 6Funded by NHS Transformation Directorate, The Health Foundation, and Wellcome Trust; study published in The Lancet Digital Health.
Why It Matters
This platform addresses critical gaps in algorithmic fairness, transparency, and efficiency for imaging AI, setting a rigorous new standard for evaluation and deployment in national health systems. Its scalable, unbiased testing approach could serve as a blueprint for clinical AI adoption across radiology and other disease areas.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.